The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).
[EN] NOVEL FUSED HETEROCYCLES AND USES THEREOF<br/>[FR] HETEROCYCLES FUSIONNES ET UTILISATIONS
申请人:ASTRAZENECA AB
公开号:WO2005111001A1
公开(公告)日:2005-11-24
This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.
This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of
H. pylori
infection.